GenScript ProBio, RVAC Medicines collabrates for GMP plasmid DNA manufacturing for mRNA Covid-19 vaccine candidate

RVAC Medicines Pte. Ltd., a biotechnology company focusing on the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines, and GenScript ProBio, a leading global Contract Development and Manufacturing Organization (CDMO), announced an agreement to establish a strategic partnership for the manufacturing of GMP-grade plasmid DNA (pDNA) for its mRNA Covid-19 vaccine candidate, RVM-V001, as well as collaboration for future therapeutic pipelines.

RVAC Medicines' RVM-V001 programme will benefit from GenScript ProBio's GMP plasmid manufacturing services. This collaboration will allow it to accelerate clinical development of its mRNA-based Covid-19 vaccine, RVM-V001, and future mRNA-based vaccines targeting infectious diseases such as Respiratory syncytial virus (RSV) and Clostriodioides difficile infection (CDI).

"We are delighted to enter into this strategic partnership with RVAC Medicines," said Dr. Brian Min, CEO of GenScript ProBio. This collaboration will allow us to use our cutting-edge GMP plasmid manufacturing platform technology to help develop the mRNA-based Covid-19 vaccine and its therapeutic candidates." "We are excited to work closely with GenScript ProBio," said Dr. Sean Fu, CEO of RVAC Medicines.

GenScript ProBio's technical strength and customer-centric approach will help to accelerate the development of RVAC's pipeline." As RVAC continues to develop its mRNA candidates, GenScript ProBio continues to supply high-quality GMP materials critical to the mission, such as plasmid DNA and the development of ancillary materials to support the mRNA manufacturing process. In addition to plasmid DNA production, the GenScript ProBio team provides consultative and expert advice on quality and regulatory expectations of agencies worldwide.

RVAC Medicines will continue to work with GenScript ProBio to support its mRNA initiatives at both the clinical and commercial stages. RVAC Medicines is an mRNA platform company headquartered in Singapore with R&D centers in Boston, MA and Shanghai, CN. Leveraging its mRNA technology and strategic partnerships, the company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. GenScript ProBio, a subsidiary of GenScript Biotech Corporation, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, vaccine, biologics discovery and antibody protein drug, aiming to accelerate drug development for customers.